Biography
Dr. Muglia obtained his Medical Degree and completed his clinical training in child neuropsychiatry at the University of Cagliari, Italy. He was then appointed as Clinical Research Fellow at the University of Toronto where he subsequently served as junior Faculty in the Department of Psychiatry.
In 2003, Dr Muglia joined GlaxoSmithKline R&D as Director in Psychiatric diseases, within the Translational Medicine and Genetics Division. In this role, he conducted several large-scale genetic studies, in collaboration with US and European medical- academic institutions that led to the identification of genetic risk factors for schizophrenia, bipolar disorder and smoking behaviour. During his years at GSK, Dr Muglia also led the early clinical development of a number of compounds.
In 2009 Dr Muglia joined, as Vice President and Early Clinical Development, NeuroSearch, a Scandinavian biotech, where he established a Clinical Pharmacology and Experimental Medicine Department. In 2011 Dr Muglia was co-founder and Chief Medical Officer of Aniona, a NeuroSearch spin-off. Dr Muglia is currently Vice President and Head of Discovery Medicine at UCB Pharma, responsible for the early phase of clinical development and research projects for Parkinson’s disease, Epilepsy and cognitive disorders